Determining the role of synthetic cannabinoids in eye pressure and tolerability measurements

A pilot, randomised, cross-over study to determine the effects of an oral, peripherally selective, synthetic cannabinoid ART27.13 on intraocular pressure

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10996483

Enrollment

Registered

2026-04-01

Start date

2026-05-29

Completion date

Unknown

Last updated

2026-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ocular hypertension or early primary open angle glaucoma Eye Diseases

Interventions

The investigational medicinal product (IMP) will be ART27.13, a synthetic, peripherally selective cannabinoid which is under development by Artelo Biosciences. The study will run as a crossover design

Eligibility

Sex/Gender

All

Age

40 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. Age = 40 years for males, = 55 years for females 2. Ocular hypertension or early primary open angle glaucoma (visual field loss, less severe than - 6 dB in a standard 24-2 Humphrey visual field test) 3. IOP between 20 and 35 mmHg inclusive

Exclusion criteria

Exclusion criteria: 1. Any other clinically significant ocular disease in either eye 2. Current liver disease or laboratory results with elevated levels of liver transaminases (AST or ALT >3 x upper limit of normal (ULN) at screening visit) 3. Renal failure (eGFR 1.5 x upper limit of normal 22. Any history of suicidal behaviour or serious suicidal ideation, defined as Category 4 or greater on the Columbia Suicide Severity Rating Scale (C-SSRS) at screening. 23. Declined consent

Countries

Northern Ireland, United Kingdom

Contacts

Public ContactMegan Campbell

DREAM@nictu.hscni.net+44 2896151447

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: May 16, 2026